4/3/2013

SK Chemicals secured the rights to develop and market THVD-201 and THVD-202, TheraVida's investigational drugs for overactive bladder and urge urinary incontinence, in South Korea. The deal entitles TheraVida to milestone fees and sales royalties.

Related Summaries